The plasminogen activation system: New targets in lung inflammation and remodeling

Current Opinion in Pharmacology

Volumn 13, Issue 3, 2013, Pages 386-393

  Schuliga, Michael ^a   Westall, Glen ^b   Xia, Yuxiu ^a   Stewart, Alastair G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPHENYLALANINE; 4 AMINOBENZAMIDINE; BENZOTHIOPHENE DERIVATIVE; FIBRIN; FIBRINOLYTIC AGENT; GLUCOCORTICOID; LIPOCORTIN 2; PHENYLALANINE DERIVATIVE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIPLASININ; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; WARFARIN;

AIRWAY REMODELING; ASTHMA; BLEEDING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; DRUG FATALITY; DRUG SELECTIVITY; DRUG TARGETING; FIBRINOLYSIS; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; NONHUMAN; PLASMINOGEN ACTIVATION; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; HUMANS; LUNG DISEASES; PLASMINOGEN ACTIVATORS;

EID: 84879076223     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.05.014     Document Type: Review

References (75)

1. WHO J.B.A. Nikolai, Khaltaev Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach 2007 155
2. R.A. El-Zein Genetic predisposition to chronic obstructive pulmonary disease and/or lung cancer: important considerations when evaluating risk Cancer Prev Res (Phila) 5 2012 522 527
3. Y.H. Khor Increased vascular permeability precedes cellular inflammation as asthma control deteriorates Clin Exp Allergy 39 2009 1659 1667
4. P.R. Tuinman Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations Crit Care 16 2012 R70
5. W.T. Huang Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis Am J Respir Cell Mol Biol 46 2012 87 95
6. S.H. Lee A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma Am J Respir Cell Mol Biol 46 2012 842 846
7. S.S. Wagers Extravascular fibrin: plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness J Clin Invest 114 2004 104 111
8. M. Del Rosso The urokinase receptor system: a key regulator at the intersection between inflammation, immunity, and coagulation Curr Pharm Des 17 2011 1924 1943
9. T. Syrovets, O. Lunov, and T. Simmet Plasmin as a proinflammatory cell activator J Leukoc Biol 92 2012 509 519
10. M. Schmitt Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 Expert Rev Mol Diagn 11 2011 617 634
11. F.J. Brims Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids Thorax 64 2009 1037 1043
12. K. Kowal Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients Folia Histochem Cytobiol 46 2008 193 198
13. W. Xiao Sputum cathelicidin: urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation Chest 128 2005 2316 2326
14. A. de Paulis Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2 J Immunol 173 2004 5739 5748
15. A.M. Bakken Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism J Vasc Surg 49 2009 1296 1303
16. Y. Wei Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1 Mol Biol Cell 12 2001 2975 2986
17. T. Tarui Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation Thromb Haemost 95 2006 524 534
18. F.J. Brims Up-regulation of the extrinsic coagulation pathway in acute asthma - a case study J Asthma 47 2010 695 698
19. S. Shetty Induction of tissue factor by urokinase in lung epithelial cells and in the lungs Am J Respir Crit Care Med 181 2010 1355 1366
20. Y. Zhang Levels of components of the urokinase-type plasminogen activator system are related to chronic obstructive pulmonary disease parenchymal destruction and airway remodelling J Int Med Res 40 2012 976 985
21. Z. Ma, D. Paek, and C.K. Oh Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation Clin Exp Allergy 39 2009 1136 1144
22. T. Iwaki, T. Urano, and K. Umemura PAI-1: progress in understanding the clinical problem and its aetiology Br J Haematol 157 2012 291 298
23. P.A. Madureira The role of the annexin A2 heterotetramer in vascular fibrinolysis Blood 118 2011 4789 4797
24. S.E. Wenzel Asthma phenotypes: the evolution from clinical to molecular approaches Nat Med 18 2012 716 725
25. A. Durham, I.M. Adcock, and O. Tliba Steroid resistance in severe asthma: current mechanisms and future treatment Curr Pharm Des 17 2011 674 684
26. C.E. Stewart uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium Thorax 67 2012 477 487
27. S.T. Holgate The sentinel role of the airway epithelium in asthma pathogenesis Immunol Rev 242 2011 205 219
28. S.H. Cho Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma J Allergy Clin Immunol 108 2001 212 214
29. W. Nie, B. Li, and Q.Y. Xiu The -675 4G/5G polymorphism in plasminogen activator inhibitor-1 gene is associated with risk of asthma: a meta-analysis PLoS ONE 7 2012 e34385
30. S. Cho Association of elevated plasminogen activator inhibitor 1 levels with diminished lung function in patients with asthma Ann Allergy Asthma Immunol 106 2011 371 377
31. E. Kuramoto Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model Am J Physiol Lung Cell Mol Physiol 296 2009 L337 L346
32. C.K. Oh PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model Biochem Biophys Res Commun 294 2002 1155 1160
33. C.E. Stewart PLAUR polymorphisms and lung function in UK smokers BMC Med Genet 10 2009 112
34. I.M. Wang Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer Am J Respir Crit Care Med 177 2008 402 411
35. J.V. Gosselink Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease Am J Respir Crit Care Med 181 2010 1329 1335
36. Q. Ding New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis Drugs 71 2011 981 1001
37. P.W. Noble, C.E. Barkauskas, and D. Jiang Pulmonary fibrosis: patterns and perpetrators J Clin Invest 122 2012 2756 2762
38. N. Nathan Interstitial lung disease: physiopathology in the context of lung growth Paediatr Respir Rev 12 2011 216 222
39. H. Kubo Anticoagulant therapy for idiopathic pulmonary fibrosis Chest 128 2005 1475 1482
40. I. Noth A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 186 2012 88 95
41. C.M. Swaisgood The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system Am J Pathol 157 2000 177 187
42. D.T. Eitzman Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene J Clin Invest 97 1996 232 237
43. H. Elokdah Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization J Med Chem 47 2004 3491 3494
44. Y. Izuhara A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates J Cereb Blood Flow Metab 30 2010 904 912
45. E. Abraham Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation J Immunol 170 2003 5644 5651
46. S. Shetty The fibrinolytic system and the regulation of lung epithelial cell proteolysis: signaling, and cellular viability Am J Physiol Lung Cell Mol Physiol 295 2008 L967 L975
47. Y.P. Bhandary Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system Am J Physiol Lung Cell Mol Physiol 302 2012 L463 L473
48. W.P. Fay, N. Garg, and M. Sunkar Vascular functions of the plasminogen activation system Arterioscler Thromb Vasc Biol 27 2007 1231 1237
49. M.M. Hoeper, M. Sosada, and H. Fabel Plasma coagulation profiles in patients with severe primary pulmonary hypertension Eur Respir J 12 1998 1446 1449
50. G. Christ Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences Thromb Haemost 86 2001 557 562
51. E.Y. Dimova, A. Samoylenko, and T. Kietzmann Oxidative stress and hypoxia: implications for plasminogen activator inhibitor-1 expression Antioxid Redox Signal 6 2004 777 791
52. J. Suzuki The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury Expert Opin Ther Targets 12 2008 783 794
53. V.A. Ploplis, and F.J. Castellino Attenuation of neointima formation following arterial injury in PAI-1 deficient mice Ann N Y Acad Sci 936 2001 466 468
54. M. Levi Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice Circulation 103 2001 2014 2020
55. J.A. Marwick, I.M. Adcock, and K.F. Chung Overcoming reduced glucocorticoid sensitivity in airway disease: molecular mechanisms and therapeutic approaches Drugs 70 2010 929 948
56. C.R. Keenan Glucocorticoid-resistant asthma and novel anti-inflammatory drugs Drug Discov Today 17 2012 1031 1038
57. A. Dijkstra SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response Eur Respir J 38 2011 1036 1043
58. G. Lippi, C. Mattiuzzi, and E.J. Favaloro Novel and emerging therapies: thrombus-targeted fibrinolysis Semin Thromb Hemost 2012
59. N.P. Lackowski Safety of prolonged: repeated administration of a pulmonary formulation of tissue plasminogen activator in mice Pulm Pharmacol Ther 23 2010 107 114
60. I. Henneke Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model Am J Respir Crit Care Med 181 2010 611 619
61. I.K. Lund Inhibitory monoclonal antibodies against mouse proteases raised in gene-deficient mice block proteolytic functions in vivo Front Pharmacol 3 2012
62. K.A. Botkjaer Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies Biochem J 438 2011 39 51
63. X.Q. Wang Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury J Immunol 177 2006 5550 5557
64. M. Sharma, M.R. Blackman, and M.C. Sharma Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model Exp Mol Pathol 92 2012 175 184
65. M. Sharma, R.T. Ownbey, and M.C. Sharma Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation Exp Mol Pathol 88 2010 278 286
66. L. Zheng Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer PLoS ONE 6 2011 e19390
67. C.M. Swaisgood Plasminogen is an important regulator in the pathogenesis of a murine model of asthma Am J Respir Crit Care Med 176 2007 333 342
68. P.G. Arndt, S.K. Young, and G.S. Worthen Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway J Immunology 175 2005 4049 4059
69. J.D. Savov Fibrinolysis in LPS-induced chronic airway disease Am J Physiol Lung Cell Mol Physiol 285 2003 L940 L948
70. E.K. Chu Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells Am J Respir Cell Mol Biol 35 2006 628 638
71. S.J. Barton PLAUR polymorphisms are associated with asthma, PLAUR levels, and lung function decline J Allergy Clin Immunol 123 2009 1391 1400 e17
72. P. Begin Association of urokinase-type plasminogen activator with asthma and atopy Am J Respir Crit Care Med 175 2007 1109 1116
73. M. Schuliga, T. Harris, and A.G. Stewart Plasminogen activation by airway smooth muscle is regulated by type I collagen Am J Respir Cell Mol Biol 44 2011 831 839
74. S.M. Carlin Urokinase signal transduction and its role in cell migration FASEB J 19 2005 195 202
75. A.M. Brooks Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma Am J Respir Cell Mol Biol 35 2006 503 511